22 Jul Persista Bio
Linda Tempelman, Ph.D., CEO
Oct. 7 | 12:00pm | FLW Ballroom F
Ithaca, NY
(Private)
Do you know someone with Type 1 Diabetes? Do you know someone who has had a cell or gene therapy? Persista Bio is poised to bring cell therapies to type 1 diabetic patients as a curative therapy – no more injections, glucose sensors or long-term disabilities. Persista Bio brings a cell implant system to enable use of the breakthrough insulin secreting stem cells without immunosuppression. Persista will present its preclinical results showing diabetes cure in immunocompetent rats with the oxygenated cell encapsulation system. Persista Bio’s implantable cell implant system is a platform to deliver other allogeneic, long term cell therapies for chronic conditions such as enzyme disorders, inflammatory diseases and chronic pain. Persista Bio is a preclinical stage company founded by the inventors of technology licensed from Cornell University and Giner, Inc.
